447results about How to "Increase drug concentration" patented technology

In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

A pharmaceutical composition comprises a solid adsorbate comprising a drug adsorbed onto a substrate and a lipophilic microphase-forming material. The solid adsorbate may also be co-administered with a lipophilic microphase-forming material to an in vivo use environment. The compositions of the present invention enhance the concentration of drug in a use environment.

The invention discloses an application of nanometer structure lipid carrier administration system in the antineoplastic drug to reverse the multiple-drug tolerance of tumour cell, which comprises the following parts: solid lipid material, liquid lipid material and antineoplastic drug, wherein the rate of the liquid lipid (such as oleic acid) is 0-30wt%; the solid lipid is selected from monoglyceride; the liquid lipid is oleic acid; the antineoplastic drug is Paclitaxel or adriablastina. The invention has highly effective cell uptaking and cytolymph condensing function with packing molecular target in the antineoplastic drug of cell, which avoids P-glucoprotein in the drug tolerant cytolymph from identifying the antineoplastic drug to reduce exclusion.

Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or biavailability in a use environment.

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property).

[Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive:

wherein each symbol is as described in the specification.

A method for interrogating the microcirculation of a subject for use in characterizing function in health and disease, monitor changes in microcirculation over time, and identify responses in microcirculation to potentially harmful or beneficial interventions. The method includes delivering a study agent to a study surface for trans-surface delivery to the microvasculature of the subject and monitoring the microvasculature of the subject in the area of the study surface. A system is also provided which includes a micro-patch for delivery of study agent to a study surface for trans-surface delivery to the microvasculature of the subject and a monitoring probe for monitoring the microvasculature of the subject in the area of the study surface.

The invention provides an embolism material composition as well as preparation method and use thereof, the embolism material composition is prepared from reactant raw materials, wherein the reactant raw materials comprise a biocompatibility material, a roentgenopaque substance and a magnetic resonance imaging substance, the roentgenopaque substance and the magnetic resonance imaging (MRI) substance are covered by the biocompatibility material. The embolism material composition not only can be directly detected by an X-ray image device, but also can be directly detected by the MRI, so that a doctor can select a detection method according to self condition of a patient and the medical device condition.

The present invention provides human binding molecules specifically binding to staphylococci and having killing activity against staphylococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from Staphylococcus.

A solubility-improved drug form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same drug form without the concentration-enhancing polymer.

The invention relates to a cyclic nucleoside phosphate compound in a structure shown as a formula I described in the specification and a preparation method and an application thereof. The cyclic nucleoside phosphate compound in the structure shown as the formula I is a precursor drug with an antivirus effect, wherein X is selected from any one of hydrogen, fluorine, chlorine, bromine and iodine, Y is selected from any one of oxygen and sulfur, and Z is arycyclo or arycyclo with 1-3 substituents; the arycyclo is selected from any one of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, 2-thienyl and 3-thienyl, the substituent on the arycyclo is selected from any one of fluorine, chlorine, bromine, iodine, trifluoromethyl, C1-3 alkyl and -OR, and R is selected from any one of trifluoromethyl and C1-3 alkyl.

The invention relates to a liver targeting pharmaceutical composition. The pharmaceutical composition for liver targeting is characterized in that protein and polyethylene glycol possessing a liver targeting function modifies an antitumor drug loading by liposome. The drug is delivered to a hepatic tissue lesions zone for increasing the drug concentration in the liver tumors position and raising the therapeutic efficacy of the liver tumors.

The invention provides human binding molecules specifically binding to West Nile virus and having West Nile virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, post-exposure prophylaxis and/or treatment of a condition resulting from West Nile virus.

Solid compositions with improved physical stability comprise an amorphous, low-solubility drug, a poloxamer, and a stabilizing polymer. The compositions provide good physical stability during storage and concentration enhancement of dissolved drug when administered to an aqueous environment of use.

The invention provides a preparation method of a target compound nano particle, relating to a preparation method of target treatment integration compound nano particles. The invention solves the technical problems of poor carrier stability and small drug-loading quantity of the traditional antineoplastic drugs. The method comprises the following steps of: preparing a methanol solution of an integrated nano particle of a Fe3O4-HCPT@SiO2 coupling porphyrin photosensitizer; and stirring the methanol solution of the integrated nano particle of the Fe3O4-HCPT@SiO2 coupling porphyrin photosensitizer, N,N-dimethylformamide and target biomolecule or antitumor drug for reacting at the room temperature, and centrifuging to obtain the target compound nano particle. Polystyrolsulfon acid (PSS) and 10-hydroxycamptothecine are absorbed on a Fe3O4 magnetic nano particle through a self-assembly mode. The preparation method is high feasibility; the target compound nano particle has a physical target function of the magnetic nano particle and an active target function of further functionally modifying the biomolecule on the surface; and the medicine concentration can be increased under a dual-target function.

Disclosed relates to a transdermal patch comprising paroxetine that is useful to reduce the side effects accompanied with the initial high drug concentration after oral administration of paroxetine and decrease the broad metabolism of the drug in the liver. Moreover, the transdermal patch comprising paroxetine of the present invention has an excellent skin permeation rate and shows high bioavailability compared with oral administration of the drug.

The invention discloses an acid sensitive polymer prodrug, nanoparticles of the prodrug and application of the nanoparticles. In the acid sensitive polymer prodrug, a polymer precursor is a vinyl ether-functionalized water-soluble A-B type two-block polymer; drug molecules are linked with the A-B type two-block polymer through an acetal bond; the acid sensitive polymer prodrug is self-assembled in water solution to form predrug micellar nanoparticles in which a polyethylene glycol hydrophilic chain segment serves as an outer surface and an anti-cancer drug bound to a polymer main chain through the acetal bond serves as a hydrophobic core. The pH sensitive prodrug and the nanoparticles of he prodrug are simple in preparation method, and good in tumor inhibitory effect; the nanoparticles also can efficiently encapsulate another hydrophobic anticancer drug; the kill capability to the cancer cell is enhanced; and the efficiency of endocytosis of the cell to the nanoparticles can be enhanced by coupling specific target molecules onto the surfaces of the nanoparticles. Thus, the inhibitory effect on the tumor cell is enhanced.

The invention provides a diaminopyrimidine compound and a composition containing the same and discloses the diaminopyrimidine compound shown as in a formula (I) and a drug combination containing the compound or salt thereof acceptable in crystal form and pharmacy, hydrate or solvent complex, stereoisomer, pro-drug or isotope variant. The diaminopyrimidine compound and the composition containing the same have excellent inhibition effect on protein kinase and have better pharmacokinetic parameter characteristics, and drug concentration of the compound in animal bodies can be increased to improve drug efficacy and safety.

The invention relates to anti-cancer drug slow release agent containing epothilone, which consists of slow release microspheres and solvent, wherein the slow release microspheres comprise anti-cancer effective components and slow release accessories; and the solvent is special solvent containing suspending agent. The anti-cancer effective components are combinations of epothilone, epothilone derivative, epothilone B, epothilone D and anticancer drugs selected from phosphoinositide 3-kinase inhibitor, pyrimidine analog and/or DNA repairase inhibitor, and the like; the slow release accessories are biocompatible high molecules such as polylactic acid and copolymer thereof, polyethylene glycol, terminal carboxyl polylactic acid copolymer, di-fatty acid and sebacic acid copolymer, poly (erucic acid dimmer-sebacic acid), poly (fumaric acid-sebacic acid), polifeprosan, polylactic acid, and the like; and the suspending agent is selected from sodium carboxymethyl cellulose and the like when the viscosity of the suspending agent is 100 to 3,000cp (at a temperature of between 20 and 30 DEG C). The anti-cancer effective components and the slow release microspheres can also be made into slow release implant agents, can effectively inhibit tumor growth through injection or placement and energy removal in tumor or tumor periphery, and can also remarkably enhance curative effect of non-operative treatment such as chemicotherapy and the like.

The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.